Arthritis Research and Therapy

Journal

Publication Venue For

  • Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.  23. 2021
  • The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect.  23. 2021
  • Urate-induced epigenetic modifications in myeloid cells.  23. 2021
  • Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.  23. 2021
  • Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.  23. 2021
  • “I wish it had a place to go”: a nominal group study of barriers to the effectiveness of non-surgical treatments for knee osteoarthritis inclusive of minority populations.  23. 2021
  • Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.  22. 2020
  • Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers.  22. 2020
  • Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available.  22. 2020
  • Physical activity measured using wearable activity tracking devices associated with gout flares.  22. 2020
  • Serious infections in people with systemic sclerosis: A national US study.  22. 2020
  • Gout is associated with an increased risk for incident heart failure among older adults: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.  22. 2020
  • Pleiotropic effect of the ABCG2 gene in gout: Involvement in serum urate levels and progression from hyperuricemia to gout.  22. 2020
  • Acute kidney injury after primary total hip arthroplasty: A risk multiplier for complication, mortality, and healthcare utilization.  22. 2020
  • Barriers to treatment optimization and achievement of patients' goals: Perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.  22. 2020
  • Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.  21. 2019
  • Population-specific factors associated with fractional excretion of uric acid.  21. 2019
  • Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - Clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.  21. 2019
  • Comparison of an interactive voice response system and smartphone application in the identification of gout flares.  21. 2019
  • Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.  21. 2019
  • Self-reported sleep quality and sleep disorders in people with physician-diagnosed gout: An Internet cross-sectional survey.  21. 2019
  • Interactions between serum urate-associated genetic variants and sex on gout risk: Analysis of the UK Biobank 06 Biological Sciences 0604 Genetics.  21. 2019
  • The relationship between ferritin and urate levels and risk of gout.  20. 2018
  • Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: A propensity-matched analysis.  20. 2018
  • Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue.  20. 2018
  • Mediation analysis to understand genetic relationships between habitual coffee intake and gout.  20. 2018
  • Gout and the risk of myocardial infarction in older adults: A study of Medicare recipients.  20. 2018
  • Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled study.  20. 2018
  • Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities.  20. 2018
  • Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.  20. 2018
  • Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort study.  20. 2018
  • Correction: Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials. [Arthritis Res Ther. 19, (2017)(267)] DOI: 10.1186/s13075-017-1476-9.  20. 2018
  • Age and fecal microbial strain-specific differences in patients with spondyloarthritis.  20. 2018
  • Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.  19. 2017
  • Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials.  19. 2017
  • Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study.  19. 2017
  • A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: Post-hoc results from the certolizumab pegol phase 4 PREDICT trial.  19. 2017
  • Gout and comorbidity: A nominal group study of people with gout.  19. 2017
  • Performance of gout definitions for genetic epidemiological studies: Analysis of UK Biobank.  19. 2017
  • Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout.  19. 2017
  • Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus.  19. 2017
  • Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: A retrospective claims analysis.  19. 2017
  • Multicenter inception cohort of enthesitis-related arthritis: Variation in disease characteristics and treatment approaches.  19. 2017
  • Population-specific association between ABCG2 variants and tophaceous disease in people with gout.  19. 2017
  • Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.  19. 2017
  • Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.  18. 2016
  • Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.  18. 2016
  • A20 suppresses canonical Smad-dependent fibroblast activation: Novel function for an endogenous inflammatory modulator.  18. 2016
  • Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: A study of Medicare claims.  18. 2016
  • The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.  18. 2016
  • Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation.  18. 2016
  • Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.  18. 2016
  • Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.  18. 2016
  • Gout-related inpatient utilization: A study of predictors of outcomes and time trends.  18. 2016
  • Minorities with lupus nephritis and medications: A study of facilitators to medication decision-making.  17. 2015
  • Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor aα agents, a retrospective cohort study.  17. 2015
  • Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout.  17. 2015
  • Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout.  17. 2015
  • Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: Analyses from large U.S. managed care cohort [Arthritis Res Ther. 2015;17:120].  17. 2015
  • Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: A retrospective cohort study.  17. 2015
  • Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: Analyses from large U.S. managed care cohort.  17. 2015
  • An update on the genetic architecture of hyperuricemia and gout.  17. 2015
  • Racial disparities in total ankle arthroplasty utilization and outcomes.  17. 2015
  • Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis.  16. 2014
  • The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout.  16. 2014
  • Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.  16. 2014
  • The impact of gout on patient's lives: A study of African-American and Caucasian men and women with gout.  16. 2014
  • Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: A qualitative study.  16. 2014
  • Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge.  16. 2014
  • Veterans Affairs databases are accurate for gout-related health care utilization: A validation study.  15. 2013
  • Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects.  15. 2013
  • Cancer risk in childhood-onset systemic lupus.  15. 2013
  • Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption.  15. 2013
  • Workshop report: 4th European crystal network meeting.  15. 2013
  • Prevalence of HLA-B27 in the New Zealand population: Effect of age and ethnicity.  15. 2013
  • Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data.  15. 2013
  • Predictors of use of pain medications for persistent knee pain after primary Total Knee Arthroplasty: A cohort study using an institutional joint registry.  14. 2012
  • Changes in pain catastrophizing predict later changes in fibromyalgia clinical and experimental pain report: Cross-lagged panel analyses of dispositional and situational catastrophizing.  14. 2012
  • The renal urate transporter SLC17A1 locus: Confirmation of association with gout.  14. 2012
  • Altered responsiveness to TGF-β results in reduced Papss2 expression and alterations in the biomechanical properties of mouse articular cartilage.  14. 2012
  • Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis.  14. 2012
  • Association between being African-American, serum urate levels and the risk of developing hyperuricemia: Findings from the Coronary Artery Risk Development in Young Adults cohort.  14. 2012
  • Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.  13. 2011
  • The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: A longitudinal observational study.  13. 2011
  • Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.  13. 2011
  • Green tea: A new option for the prevention or control of osteoarthritis.  13. 2011
  • The SLC2A9 nonsynonymous Arg265His variant and gout: Evidence for a population-specific effect on severity.  13. 2011
  • Anticitrullinated protein antibody (ACPA) in rheumatoid arthritis: Influence of an interaction between HLA-DRB1 shared epitope and a deletion polymorphism in glutathione s-transferase in a cross-sectional study.  12. 2010
  • Applying science in practice: The optimization of biological therapy in rheumatoid arthritis.  12. 2010
  • Advances in gout: Some answers, more questions.  12. 2010
  • The delivery of evidence-based preventive care for older Americans with arthritis.  12. 2010
  • Effect of duloxetine in patients with fibromyalgia: Tiredness subgroups.  12. 2010
  • Preventive health services for systemic lupus erythematosus patients: Whose job is it?.  12. 2010
  • Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: Confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance.  12. 2010
  • Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis.  12. 2010
  • Effects of lifestyle physical activity on perceived symptoms and physical function in adults with fibromyalgia: Results of a randomized trial.  12. 2010
  • Progress in osteoporosis and fracture prevention: Focus on postmenopausal women.  11. 2009
  • The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets.  11. 2009
  • Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?.  11. 2009
  • Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus.  10. 2008
  • Leg-length inequality is not associated with greater trochanteric pain syndrome.  10. 2008
  • Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine..  10:120. 2008
  • Epidemiology, risk factors, and lifestyle modifications for gout.  8. 2006
  • No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome.  8. 2006
  • International Standard Serial Number (issn)

  • 1478-6354
  • Electronic International Standard Serial Number (eissn)

  • 1478-6362